Boston, MA (updated) - The rate of recurrent CV events over two years following an acute ST-segment-elevation MI (STEMI) fell with twice-daily rivaroxaban (Xarelto, Bayer/Janssen) therapy in the ...

Longer times from symptom onset to randomization equaled a smaller—or perhaps no—advantage for Impella vs standard care.

Data provide further insight into how the timing of PCI may affect outcomes in STEMI patients at risk for future cardiovascular events ORLANDO, Fla., Nov. 16, 2011 /PRNewswire/ -- An analysis of the ...

An intracoronary injection of nitrite during primary PCI does not reduce infarct size in STEMI patients, according to a small, randomized proof-of-concept trial published in the January 30, 2015, ...

Please provide your email address to receive an email when new articles are posted on . Among patients who underwent primary PCI for STEMI, results from a recent study have suggested that the TIMI ...

Dallas, TX - Low-molecular-weight heparin (LMWH) may be superior to unfractionated heparin in the treatment of patients with ST-elevation MI (STEMI) receiving thrombolytic therapy in the modern era, ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Ticagrelor after fibrinolytic therapy in patients younger than 75 years with STEMI may not reduce ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window DENVER -- Just 6 months of dual antiplatelet therapy (DAPT) may ...

SEATTLE, July 16, 2024 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following ...

When timely angioplasty is unavailable to older ST-segment elevation myocardial infarction (STEMI) patients, a modified pharmaco-invasive reperfusion strategy could be reasonable, according to the ...